The Ethics of Clinical Research on Diseases of the Fetus and Newborn: Balancing Benefit–Risk, Autonomy, and Maternal–Fetal Interests
American Journal of Perinatology · 2026-07 · 43 (10) · 1375-1381
DOI: 10.1055/a-2764-2202 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Perinatology, online erschienen am 30.12.2025. Verfasst von Robert M Nelson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Drug Development, Child Health Innovation Leadership Department, Johnson & Johnson, Raritan, New Jersey, United States. Hauptthemen laut MEDLINE: Thrombocytopenia, Neonatal Alloimmune, Erythroblastosis, Fetal, Biomedical Research. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Ethik in der Pflege
Abstract (Originalsprache)
Pregnant persons historically have been excluded from clinical trials. Recently, there has been a shift from exclusion toward inclusion of pregnant persons in research while acknowledging the complexity of reproductive ethics and the intertwined interests of the pregnant person and fetus. Our objective was to use a principle-based approach to review the ethics of clinical research concerning pregnancy-related disorders that predominantly affect fetal well-being. Ethical principles are applied to the design of interventional trials in two rare conditions of pregnancy, hemolytic disease of the fetus and newborn (HDFN) and fetal and neonatal alloimmune thrombocytopenia (FNAIT). Severe HDFN and FNAIT are fetal and neonatal diseases caused by maternal alloantibodies with potential outcomes including maternal and neonatal morbidity, preterm delivery, and fetal or neonatal death. Early-onset severe HDFN was the initial indication for a phase 2 open-label study of nipocalimab in pregnancy, given poor outcomes after prior severe HDFN pregnancy(s). After establishing proof of concept, a phase 3 randomized placebo-controlled study was initiated based on the ethical principles of equipoise and generating socially valuable data to support the efficacy and safety of nipocalimab in severe HDFN. However, off-label use of antenatal intravenous immunoglobulin (IVIg) in standard-risk FNAIT pregnancies made a randomized placebo-controlled study challenging. Thus, the FNAIT clinical program for nipocalimab in pregnant persons with standard-risk FNAIT includes a randomized, placebo-controlled study limited to sites that do not use antenatal IVIg, and a global randomized open-label study of nipocalimab or IVIg. Knowledge of the clinical course and management of severe HDFN and FNAIT, the non-clinical and non-pregnant human clinical evidence, and input from physicians, patients, and health authorities permitted the design of clinical protocols that satisfy the principles of beneficence and non-maleficence in these rare and complex diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pediatric Drug Development, Child Health Innovation Leadership Department, Johnson & Johnson, Raritan, New Jersey, United States.
- Bioethics-Based Science and Technology Policy, Office of the Chief Medical Officer, Johnson & Johnson, New Brunswick, New Jersey, United States.
- Translational Science (Autoantibody), Johnson & Johnson, Cambridge, Massachusetts, United States.
- Global Regulatory Affairs, Johnson & Johnson, Raritan, New Jersey, United States.
- Department of Maternal Fetal Immunology, Johnson & Johnson, Spring House, Pennsylvania, United States.
- Department of Immunology, Johnson & Johnson, Raritan, New Jersey, United States.
ORCID-Profile: Kenneth J Moise
Zitieren
APA
Nelson, R. M., Childers, K., Ling, L. E., Alquier, L., Komatsu, Y., Schwartz, L., Stevens, A. M., Tjoa, M. L., Moise, K. J., & Goldkind, S. F. (2026). The Ethics of Clinical Research on Diseases of the Fetus and Newborn: Balancing Benefit–Risk, Autonomy, and Maternal–Fetal Interests. American Journal of Perinatology, 43(10), 1375-1381. https://doi.org/10.1055/a-2764-2202
Vancouver
Nelson RM, Childers K, Ling LE, Alquier L, Komatsu Y, Schwartz L, et al. The Ethics of Clinical Research on Diseases of the Fetus and Newborn: Balancing Benefit–Risk, Autonomy, and Maternal–Fetal Interests. American Journal of Perinatology. 2026;43(10):1375-1381. doi:10.1055/a-2764-2202
BibTeX
@article{Nelson2026,
author = {Nelson, Robert M and Childers, Karla and Ling, Leona E and Alquier, Lori and Komatsu, Yosuke and Schwartz, Lisa and Stevens, Anne M and Tjoa, May Lee and Moise, Kenneth J and Goldkind, Sara F},
title = {The Ethics of Clinical Research on Diseases of the Fetus and Newborn: Balancing Benefit–Risk, Autonomy, and Maternal–Fetal Interests},
journal = {American Journal of Perinatology},
year = {2026},
volume = {43},
number = {10},
pages = {1375--1381},
doi = {10.1055/a-2764-2202}
}
EUVIMED